10x Genomics, Inc.
General ticker "TXG" information:
- Sector: Health Care
- Industry: Medical - Healthcare Information Services
- Capitalization: $2.1B (TTM average)
10x Genomics, Inc. follows the US Stock Market performance with the rate: 61.1%.
Estimated limits based on current volatility of 3.2%: low 46.38$, high 49.41$
Factors to consider:
- Earnings expected soon, date: 2026-08-06 amc
- Total employees count: 1178 (-9.8%) as of 2025
- US accounted for 54.7% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Fluctuating operating results, Funding dependency, Compete successfully, Develop new products successfully, Manage product transitions well
- Current price 88.6% above estimated high
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [12.23$, 25.07$]
- 2026-12-31 to 2027-12-31 estimated range: [11.59$, 23.91$]
Financial Metrics affecting the TXG estimates:
- Negative: with PPE of -38.3 at the end of fiscal year the price was high
- Negative: negative Operating income
- Positive: 0.30 < Operating cash flow per share per price, % of 6.62
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Inventory ratio change, % of -4.47 <= -0.76
- Negative: negative Net income
- Positive: -4.44 < Investing cash flow per share per price, % of -0.65
Short-term TXG quotes
Long-term TXG plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $618.73MM | $610.78MM | $642.82MM |
| Operating Expenses | $884.06MM | $805.34MM | $703.81MM |
| Operating Income | $-265.33MM | $-194.56MM | $-60.98MM |
| Non-Operating Income | $16.57MM | $16.86MM | $21.08MM |
| Interest Expense | $0.03MM | $0.00MM | $0.00MM |
| R&D Expense | $331.31MM | $264.70MM | $238.63MM |
| Income(Loss) | $-248.76MM | $-177.70MM | $-39.91MM |
| Taxes | $6.34MM | $4.93MM | $3.64MM |
| Net Income(Loss)* | $-255.10MM | $-182.63MM | $-43.54MM |
| Stockholders Equity | $741.04MM | $710.13MM | $796.33MM |
| Inventory | $73.71MM | $83.11MM | $56.34MM |
| Assets | $965.14MM | $918.64MM | $1,041.37MM |
| Operating Cash Flow | $-15.20MM | $6.66MM | $136.05MM |
| Capital expenditure | $49.52MM | $12.39MM | $5.93MM |
| Investing Cash Flow | $133.49MM | $-32.63MM | $-13.44MM |
| Financing Cash Flow | $13.67MM | $10.91MM | $6.80MM |
| Earnings Per Share** | $-2.18 | $-1.52 | $-0.35 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.